








































































































Nwakanma et al Cardiothoracic Transplantation
TXiscussion
r G. Alexander Patterson (St Louis, Mo). This study was under-
aken primarily to determine whether there was any difference in
utcome between SLT and BLT recipients of older age. The authors
ave noted the expected preoperative differences between BLT and
LT recipients with respect to age, preoperative FVC, and pulmonary
rtery pressure, all of which you would expect to be different, but I
ould argue those differences are clinically irrelevant.
There are a number of observations in this report that I think are
mportant. First, perioperative mortality was surprisingly low in this
ge group. Our own experience at Washington University is similar,
ctually. Among 168 patients over the age of 60, our operative
ortality rate was only 2.4%. I think low mortality rates are achiev-
ble in these patients. Mortality did not differ between SLT and BLT
ecipients. One-year and 5-year survivals are similar for both of these
rocedures in older patients but lower than we would expect and
ower than previously has been reported for younger recipients. In
ddition, the study provides important confirmation of previously
eported data suggesting poorer outcome with older donors and do-
ors with a significant smoking history. I know we are going to be
alking about that in a subsequent presentation. However, there are
ome limitations in this study that I think are relevant. First of all, it
oes suffer from the defects of a multicenter, multiprotocol registry
ith limited data fields. Dr Nwakanma, you did acknowledge that in
our slides, but I think of more importance is that this information was
ccumulated in an era predating the current allocation scheme, which
llocates priority for donor lungs by severity of disease rather than by
aiting time. The former system of priority by waiting time favored
he patients with emphysema on the waiting list. The current system
f priority by severity of disease favors the patients with fibrosis. As
ou might expect, 65% of the recipients reported from this previous
ra in the current report had emphysema and only 26% had fibrosis.
e should be very careful in extrapolating these results in elderly
atients to the current era. It is likely that in future years older patients
ith fibrosis will predominate on our waiting list. The authors have
learly demonstrated what is already known, that patients with fibrosis
ave poorer immediate and long-term outcome than patients with
bstructive lung disease after LTx.
I have two questions. Dr Nwakanma, could you comment on
hat you think the current algorithm or the current lung allocation
coring system might do to these results looking forward? Also, I
hink it would be helpful if you could tell us where that 87-year-old
atient received the LTx, because I think the program directors of
hat program need psychiatric help.
Dr Nwakanma. Thank you, Dr. Patterson, for your time and
or commenting on our paper.
To answer your first question, as you mentioned, the new lung
llocation system actually bases on severity of disease. We believe that
hat we have been able to show with these data is that the patients who
re older than 60 do not have a worse outcome with BLT in a recent
ohort. Therefore, if the organ is available and the elderly patient has a
igh lung allocation system score, then the patient should not be deprived
f receiving bilateral lungs. The new system was only implemented in, I
elieve, the spring of 2005, so time will tell the actual effect of the new
llocation system on the choice of SLT versus BLT in elderly patients.
As regards your second question, we had the same question in
ur minds when we saw that there was an 87-year-old patient. We
riple-checked by the transplant identification and by the donor f
The Journal of Thoracicdentification, and we contacted UNOS several times. They con-
rmed verbally and in writing that there was an 87-year-old
ecipient according to their data. Whether that was a mistake or
ot, they could not clarify, but they told us it was an actual
ecipient, and the patient actually received the LTx in July 1998,
ut the location of the program where the transplantation was
erformed is confidential information, as you might imagine. It
as not done at Johns Hopkins.
Dr Thomas C. Wozniak (Indianapolis, Ind). I like this trial because
t shows that the mortality really is not any different for BLT. Like
robably most programs, we are listing more and more people over the
ge of 60. In the past we had traditionally favored SLT in those patients
f they could tolerate that. However, what we are beginning to see now are
ore patients whom we really wish we had treated with BLT rather than
LT. They have survived, but I do not believe they have recovered and
eached a functional quality of life that they could have, and they have
truggled. Do you have any way to look at the functional outcome as
pposed to the actual survival in these patients?
Dr Nwakanma. Thank you for your question. That’s a nice
omment. We really wish we could, but the data do not provide
eliable information to make a good conclusion in terms of func-
ional outcomes.
Dr Robert Shen (Charlottesville, Va). I was quite interested by the
ndings of your multivariate analysis, which showed that the only two
actors that were predictive of increased mortality were smoking greater
han 20 years in the donor and the diagnosis of IPF. The most recent
nnual report of the ISHLT data shows that body mass index
nd advanced age of the recipient were the only two factors in
hat registry that were predictive of increased mortality. Do you
ave a hypothesis or an explanation for the difference in the two
utcomes based on the two different registries?
Dr Nwakanma. Thank you for your questions. The 2005
SHLT registry report by Trulock and colleagues was looking at
atients mainly from 1994 to 2003. Our patient cohort includes
atients from 1998 to 2004, and, as I mentioned, we chose this
eriod to represent mainly the modern cohort and reflect the
odern improvements in LTx. It is possible that a difference in the
redictors of mortality is based on the different time era. More-
ver, the registry report looks at all patients, but our analysis
ooked at only those who are older than 60 years. Those differ-
nces might explain the different results.
Dr Bryan F. Meyers (St Louis, Mo). I am interested in your results
ith regard to IPF and the absence of an effect of SLT versus BLT in
hese older patients. Your results are particularly interesting in light of the
act that Meyer and colleagues, last year, came to an opposite conclu-
ion—that older patients did worse with the BLT for fibrosis than with
LT—and I think it was probably based on much the same data. I
ondered if you are aware of that report and if you have any estimate
f why the two reports come to different conclusions.
Dr Nwakanma. Thank you for that question. The answer also lies
n the answers I gave for the previous question. The report from
eyer and colleagues, reported in 2005, was looking, again, at all
atients regardless of age who had native disease of IPF. However,
hen they did a subanalysis that looked at only patients who were 60
o 69 years old, they actually found no difference between SLT and
LT in that subgroup of patients according to that particular paper.
lthough we have about the same time period, they actually alsoound no difference for the subgroup between 60 to 69 years old.
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